Influencing factors of secondary primary cancer in patients with acute lymphoid leukemia / 公共卫生与预防医学

Objective To analyze the influencing factors of second primary cancer (SPC) in patients with acute lymphoblastic leukemia (ALL). Methods The Surveillance, Epidemiology and End Results database of the National Cancer Institute was used to extract data, and SEER*Stat program 8.4.0 was used to calculate the standardized incidence rate ratio (SIR) and absolute excess rate (AER). In addition, Cox regression models were used to estimate the hazard ratio (HR) of different age, race, sex, chemotherapy, and radiation and other factors for secondary tumors by R 4.2.1, and Kaplan-Meier method was used to plot the cumulative incidence. Results A total of 22 407 cases were included, and the person-years of follow-up were 142780.82. There was a total of 436 SPC cases, 32 of which developed multiple cancers. The median time of secondary cancers was 47.5 months. Patients with ALL had a higher risk of SPC than the general population (SIR=2.27; 95% , CI:2.07-2.50), and the most observed SPC was lymphatic and hematopoietic system, with an SIR of 6.96 (95% CI:5.94-8.11). The risk of SPC in ALL patients diagnosed in different time periods showed an upward trend, from 1.98 in 2000 to 2.38 in 2019. With the increase of age, the risk of SPC in ALL patients gradually decreased. Chemotherapy reduced the risk of SPC (HR=0.26; 95%CI: 0.19-0.36), while radiotherapy increased the risk of SPC by 59.60% (HR=1.57; 95% CI: 1.23-2.00). Conclusion In the future, chemotherapy is recommended for ALL patients to reduce radiation exposure during radiotherapy, and more attention should be paid to the health status of ALL patients within 1-5 years after their onset.

Síndrome del psoas maligno secundario a cáncer de cuello uterino / Malignant psoas syndrome secondary to uterine cervical carcinoma

Resumen Una mujer de 40 años se internó de forma programada para recibir quimioterapia por una leucemia linfoblástica aguda (LLA) B común de alto riesgo, diagnosticada 10 meses antes a raíz de hemato mas y petequias en los miembros inferiores, y metrorragia. En ese momento, presentaba trombocitopenia y una ecografía ginecológica transvaginal normal. Al ingreso de la internación programada, se quejó de dolor inguinal izquierdo con irradiación al muslo e impotencia funcional de 3 meses de evolución, dolor en fosa ilíaca derecha y diarrea. En el examen físico tenía dolor a la palpación profunda en la fosa ilíaca derecha y signo del psoas positivo a la izquierda. La tomografía de abdomen y pelvis reveló una imagen compatible con un absceso del psoas izquierdo y signos de tiflitis. La biopsia del psoas izquierdo demostró infiltración por nidos y cordones de carcinoma escamoso queratinizante moderadamente diferenciado. El examen ginecológico dirigido evidenció anomalías macroscópicas del cuello uterino correlacionadas con el mismo diagnóstico histopatológico. Los se gundos cánceres primarios más frecuentemente asociados a LLA son linfoma de Hodgkin, cáncer escamoso de piel, tumores endocrinos, cáncer renal, linfoma no-Hodgkin y cáncer de mama. Las metástasis musculares de tumores sólidos son infrecuentes, y habitualmente provienen del pulmón, riñón, tiroides y melanoma. El síndrome del psoas maligno es causado por infiltración neoplásica del músculo. El diagnóstico diferencial debe realizarse con el absceso del psoas, que puede originarse en una tiflitis si es secundario. No hemos podido encontrar registros de cáncer de cuello uterino como segundo cáncer primario luego de LLA.

Abstract A 40-year-old woman was scheduled to receive chemotherapy for a high-risk common B-cell acute lymphoblastic leukemia (ALL), diagnosed 10 months earlier in the wake of lower limb bruising and petechiae, and metrorrhagia. At that time, she had thrombocytopenia and a normal transvaginal gynecological ultrasound. Upon admission, she complained of a 3-month history of incapacitating left groin pain radiated to the thigh, and right lower quadrant abdominal pain associated with diarrhea. On physical examination, she had tenderness in the right iliac fossa and a positive psoas sign on the left. Computerized scan of the abdomen and pelvis reported an image compatible with a left psoas abscess and signs of typhlitis. The biopsy of the left psoas muscle demonstrated infiltration by nests and cords of moderately differentiated keratinizing squamous carcinoma. Gynecological examination revealed macroscopic abnormalities of the cervix correlated with the same histopathological diagnosis. The second primary cancers most frequently associated with ALL are Hodgkin lymphoma, squamous skin cancer, endocrine tumors, kidney cancer, non-Hodgkin lymphoma, and breast cancer. Muscle metastases from solid tumors are rare, and usually arise from the lung, kidney, thyroid, and melanoma. Malignant psoas syndrome is caused by neoplastic infiltration of the muscle. The differential diagnosis should be made with a psoas abscess, which may arise from typhlitis if secondary. We have not been able to find records of cervical cancer as second primary cancer after ALL.

Real-world study evaluating the incidence of liver damage conditions in patients with primary liver cancer using immune checkpoint inhibitor-based combination therapy / 中华肝脏病杂志

Objective: To evaluate the incidence of immune checkpoint inhibitor-based combination therapy-induced liver damage in patients with primary liver cancer. Methods: Clinical data of 65 hospitalized cases of primary liver cancer treated with programmed cell death-1 its ligand programmed death-ligand 1 (PD-1/PD-L1) antibody in the Department of Infectious Diseases of the Second Affiliated Hospital of Chongqing Medical University from January 1, 2018 to March 31, 2021 were retrospectively analyzed. The degree of liver injury before and after treatment was assessed according to CTCAE v5.0. Patients were grouped according to gender, age, presence or absence of cirrhosis, baseline Child-Pugh score, BCLC stage, and treatment regimen to compare the incidence of liver injury under different conditions. The χ (2) test or rank-sum test was used for comparison among multiple groups. Results: 46 cases (70.77%) had liver damage of any grade according to the CTCAE V5.0 criteria during the treatment and observation period. All 6 cases who received standardized anti-hepatitis B virus (HBV) treatment developed liver damage. 10 (15.38%), 15 (23.08%), 19 (29.23%), and 2 (3.08%) cases had grade 1, 2, 3, and 4 liver damage respectively. There was no statistically significant difference in the incidence of liver damage between male and female patients (68.33% and 100%, P = 0.180). There was no statistically significant difference in the incidence of liver damage among different age groups (P = 0.245). The incidence of liver damage in cirrhotic and non-cirrhotic group was 72.22%, and 63.64% (P = 0.370), respectively. The incidence of liver damage in patients with baseline Child-Pugh class A, B, and C were 71.43%, 61.11% and 100%, respectively, and the difference was not statistically significant (P = 0.878). The incidence of liver damage was not statistically significantly different under different BCLC stages (P = 1.000). The incidence of liver damage in the PD-1/PD-L1 antibody monotherapy, PD-1/PD-L1 antibody combined with targeted drug therapy, and PD-1/PD-L1 antibody combined with TACE/radiofrequency ablation treatment group were 60.00%, 67.85%, and 86.67%, respectively. There was no statistically significant difference in the incidence of liver damage between the treatment regimen (P = 0.480). Conclusion: Immune checkpoint inhibitor therapy-induced liver damage is common in patients with primary liver cancer; however, it rarely severely endangers the patient's life. Additionally, patient's gender, age, presence or absence of cirrhosis, baseline liver function, BCLC stage and the immunotherapy regimen has no effect on the incidence of immune-related liver damage.

Whether radiotherapy for pelvic tumor increases the risk of second primary cancer / 中华放射肿瘤学杂志

Second primary cancer (SPC) is one of the main late toxicities of tumor therapy. According to statistics, one out of every 12 cancer survivors will develop SPC, and more than half of the cancer survivors will die of SPC. At present, approximately 70% of cancer patients receive radiotherapy (RT) throughout the course of disease. Whether high-dose radiation will increase the risk of SPC has captivated widespread attention. Among them, most pelvic tumor patients should receive RT because of the high incidence. In this article, relevant studies of potential pathogenesis of SPC, impact of different RT techniques, selection of RT timing, and RT for male, female and pediatric pelvic tumors were reviewed, aiming to investigate whether pelvic RT will increase the risk of SPC.

Deriving primary cancer cell cultures for personalized therapy

ABSTRACT Cancer is the second-leading cause of death in the world, accounting for one out of six deaths. Consequently, there is an urgent need for new and more effective therapeutic options as well as drug screening methods. Immortal, “stable” cancer cell lines have been employed since the past century to assess drug response but face several disadvantages. They often accumulate new genetic aberrations due to long-term culture and lack the indisputable heterogeneity of solid tumors, therefore, compromising the recapitulation of molecular features from parental tumors. Primary cancer cells have emerged as an attractive alternative to commercial cell lines since they can preserve such properties more closely. Here, we provide an overview of the basic concepts underlying generation and characterization of primary cell cultures from tumor samples. We emphasize the advantages and disadvantages of using these types of cancer cell cultures, and we make a comparison with other types of cultures used for personalized therapy. Finally, we consider the use of primary cancer cell cultures in personalized therapy as a means to improve drug response prediction and therapeutic outcomes.

Clinicopathologic analysis of 38 male breast cancers / 中国实用外科杂志

OBJECTIVE: To analyze the clinicopathologic characteristics and molecular subtype in male breast cancer(MBC). METHODS: The clinical features, histological features and molecular subtype of 38 cases of male breast cancers admitted from January 2013 to March 2019 in Clinical Pathology Diagnostic Center of Ningbo were analyzed retrospectively. RESULTS: Thirty-eight patients were diagnosed with MBC, accounting for 0.83% of all the breast cancer in the same term. The median age was 68.5(range from 24 to 88). Tumor were located in left side in 20 cases, right side in 18 cases. Twenty-nine cases were diagnosed as invasive ductal carcinoma, two cases of secretory breast cancer, one case of invasive solid papillary carcinoma, two cases of intraductal papillary carcinoma with microinvasive, and four cases of encapsulated papillary carcinoma(two of them with microinvasive). Sixteen patients had lymphatic metastasis when the tumor was diagnosed. Imunohistochemically, ER was positive in 36 cases, while PR was positive in 35 cases.Eighteen cases were Luminal A type, while sixteen were Luminal B type and two cases were basal-like subtype.CONCLUSION: MBC is a rare malignant neoplasm, and most patients are diagnosed older and at advanced clinical stage,what is more, there is more possibility of second non-breast primary cancer. All suggesting that early diagnosis,treatment and more intensive surveillance are important. MBC needs further study.

Clinical and pathological features of 50 cases of double primary cancer in the stomach and colorectum / 中国肿瘤临床

Objective: To discuss the clinical and pathological features of double primary cancer (DPC) in the stomach and colorectum. Methods: The data of 50 patients who were diagnosed with DPC and underwent surgery at The Affiliated Tumor Hospital of Xinjiang Medical University between June 2015 and June 2018 were retrospectively analyzed. The data that were analyzed included the age of onset, gender ratio, tumor stage, pathological type, and other characteristics. Thirty patients had synchronous DPC (SC), and 20 had metachronous DPC (MC). Statistical analysis was performed in the two groups. Results: The mean age was (65.44±11.94) years with 37 men and 13 women. The ratio of men to women was 2.85:1. The tumor-node-metastasis (TNM) stages were mainly stagesⅡ-Ⅲ(47/50, 94.0%). The pathological pattern was mainly adenocarcinoma (35/50, 70.0%). There was no significant difference in the pathological type, differentiation degree, and tumor stage between the first and second primary cancers in patients with MC (P<0.05). The age of patients diagnosed with SC was older than that of patients diagnosed with MC [(68.87±8.83) years vs. (60.30±14.22) years] (P=0.011). SC and MC showed no differences in gender, TNM stage, pathological type, differentiation degree, and smoking and alcohol consumption status. Conclusions: Screening for second primary cancer should be strengthened over the age of 50 years for patients with gastric cancer or colorectal cancer.

Gastric carcinoma and acute myeloid leukemia: A case report of a double malignancy

A double malignancy involving a solid organ and hematopoieteic system is rare. We report an interesting case of gastric adenocarcinoma with subsequent development of acute myeloid leukemia, in the absence of any therapeutic intervention.

Progress of multiple primary esophageal carcinoma / 肿瘤研究与临床

Multiple primary esophageal carcinoma (MPEC) is a special type of esophageal carcinoma, including multiple sites in esophagus and carcinomas in esophagus and other organs that mostly occurs in the head and neck as well as stomach.With the great advance of researches,knowledge and diagnostic technique, the diagnosis rate of MPEC has been improved.The biological behavior, clinical characteristics, and prognosis of MPEC differ from esophageal cancer alone.This paper summarizes the research progress of MPEC.

A Case of Synchronous Lung Squamous Cell Carcinoma and Diffuse Large B-cell Lymphoma / 대한내과학회지

A 65-year-old male was referred to our hospital for evaluation of a right pleural effusion. Thoracic computed tomography (CT) revealed a huge central mass with right hilar and subcarinal lymph node conglomerates. An endobronchial mass was incidentally found in the right upper lobe bronchus, and endobronchial ultrasound-guided transbronchial needle biopsy of the mediastinal lymph nodes was thus also performed at the time of bronchoscopy. The two biopsies revealed squamous cell carcinoma and diffuse large B-cell lymphoma (DLBCL), respectively. As the pathology of the mediastinal lymph nodes was unknown, the lung cancer could not be accurately staged. Thus, we treated the DLBCL; follow-up positron emission tomography/CT after two cycles of chemotherapy showed that the conglomerate mass had disappeared but the right upper lobe lesion remained. Lung cancer staging thus became more accurate and radical treatment could be considered. To the best of our knowledge, this is the first report of a co-existing squamous cell carcinoma of the lung and DLBCL of the intrapulmonary lymph nodes.

A rare case report of primary fallopian tube carcinoma in 40 year old female

Primary cancer of the fallopian tube is very rare. An average of 20 to 30 new cases are reported each year. The incidence of this cancer varies from 0.14 to 1.8% of all Gynecological cancers. It is possible that the true incidence of PFTC has been underestimated because PFTC may have been mistakenly identified as ovarian tumors during initial surgery and/or during microscopic examination by a pathologist, as the histological appearance of these tumors are identical. Here in we report a classic case of PFTC in 40 year old female.

Clinicopathologic Characteristics and Prognosis of Tongue Squamous Cell Carcinoma in Patients with and without a History of Radiation for Nasopharyngeal Carcinoma: A Matched Case-Control Study / Journal of the Korean Cancer Association, 대한암학회지

PURPOSE: Previous studies reported an association between an increased risk of tongue cancer and radiation treatment for nasopharyngeal carcinoma (NPC). This study compared the clinicopathologic characteristics and outcomes of tongue squamous cell carcinoma (TSCC) in patients with and without a history of radiotherapy for NPC. MATERIALS AND METHODS: From 1965 to 2009, a total of 73 patients were diagnosed with TSCC with a history of radiotherapy for NPC. The patients were matched in a 1:3 ratio with patients with sporadic TSCC according to age, sex, and year of the TSCC diagnosis. The primary endpoint was the overall survival. RESULTS: The median interval from NPC to TSCC was 82 months. The NPC survivors were more likely to be diagnosed with a more advanced T classification, less likely to have lymph node involvement, and more likely to have the tumor located in the dorsum of the tongue than sporadic TSCC. Regarding the histologic characteristics, the NPC survivors were more likely to have a weak lymphocytic host response, low tumor budding, and low risk of a worse pattern of invasion. The sporadic TSCC patients had a better overall survival (hazard ratio, 0.690; p=0.033) than the NPC survivors. In competing risks analysis, the cumulative incidence functions for the competing event (documented non-tongue cancer death) were significantly higher in the NPC survivors (Gray's test, p=0.001). CONCLUSION: TSCC patients with a history of radiotherapy for NPC appear to have particular clinicopathologic features, a poorer survival, and are more likely to die from non-tongue cancer causes than those with sporadic TSCC.

Quadruple Metachronous Primary Malignant Neoplasm in the Head and Neck and Digestive Tract / 대한내과학회지

Multiple primary cancers, i.e., the occurrence of multiple malignant neoplasms in a single patient, were first reported by Billorth in 1889. The incidence is low but increasing gradually due to developments in cancer diagnosis, early detection, and prolongation of life. In Korea, double primary cancers are occasionally reported. However, the simultaneous presence of four primary cancers in a single patient is rare. Recently, we experienced the case of a 68-year-old male diagnosed with quadruple primary cancers involving the esophagus, tonsils, liver and buccal mucosa. Here, we report this very rare case of four metachronous primary neoplasms and provide a brief review of the related literature.

Metástasis hepática como forma de presentación de cáncer / Hepatic metastases as the onset cancer

INTRODUCCIÓN: la metástasis hepática representa una fase avanzada del cáncer; en algunos casos el tratamiento logra un beneficio en la supervivencia. OBJETIVO: caracterizar pacientes con metástasis hepática como forma de presentación del cáncer. MÉTODOS: estudio descriptivo, longitudinal y prospectivo de 60 pacientes con metástasis hepática atendidos en el Hospital “Hermanos Ameijeiras”, desde enero-2010 a junio-2013. Se analizaron las variables seleccionadas mediante el cálculo de números absolutos y porcentajes (%) como medidas de resumen para variables cualitativas, media y desviación estándar para variables cuantitativas. Se utilizó un nivel de significación del 5 % y las estimaciones fueron interpretadas como corresponde. RESULTADOS: la edad media fue 59 años; predominaron los varones (65 %). Como síntoma/signo principal se destacaron la hepatomegalia (66,6 %) y el dolor abdominal (56,6 %). Para determinar la condición física del paciente al momento del diagnóstico se empleó la escala del Grupo Oncológico Cooperativo del Este: 46,7 % tuvo un performance status (PS) grado 0, seguido del grado 3 con 20 %. La variedad histológica preponderante fue adenocarcinoma (38,3 %). No se logró identificar tumor primario en el 28,3 % de los casos. El tumor primario identificado con más frecuencia fue el de páncreas con 15 %. Los sitios de metástasis coincidentes más frecuentes fueron ganglios linfáticos (16,6 %) y pulmones (10 %). CONCLUSIONES: la metástasis hepática como forma de presentación del cáncer fue más frecuente en varones y en edades superiores a 60 años; la hepatomegalia constituyó la manifestación clínica principal y el adenocarcinoma la histología más usual. No se logró identificar tumor primario en el 28,3 % de los casos y el sitio primario identificado más frecuente fue páncreas; los ganglios linfáticos y los pulmones fueron los órganos más comúnmente afectos por metástasis coincidentes.

INTRODUCTION: liver metastases represent an advanced stage of cancer; in some cases treatment achieves a survival benefit. OBJECTIVE: characterize patients with liver metastasis as the presenting symptom of cancer. METHODS: a descriptive, longitudinal, prospective study was conducted in 60 patients with liver metastases treated at Hermanos Ameijeiras Hospital from January 2010 to June, 2013. Variables were selected by calculating absolute numbers and percentages (%) as summary measures for qualitative variables, mean and standard deviation for quantitative variables. A significance level of 5% was used and estimates variables were interpreted as corresponding. RESULTS: the mean age was 59 years; male patients were significantly more (65 %). As a main symptom / sign hepatomegaly (66.6 %) and abdominal pain (56.6 %) were highlighted. The physical condition of these patients at diagnosis was determined by the scale of Eastern Cooperative Oncology Group: 46.7 % had a performance status (PS) grade 0, followed by grade 3 (20 %). predominant histological type was adenocarcinoma (38.3 %). It was not possible to identify the primary tumor in 28.3 % of cases. The pancreas was the most common primary tumor site (15 %). The most frequent coincident metastases sites were lymph node (16.6 %) and lung (10 %). CONCLUSIONS: liver metastases as forms in which this disease is presented was more common in men and older than 60 years of age. Hepatomegaly was the main clinical manifestation and the most usual histology was adenocarcinoma. It was not possible to identify the primary tumor in 28.3 % of cases and most frequently identified primary site was pancreas. Lymph nodes and lungs were the most commonly affected organs by coincident metastases.

Comparative study of synchronous primary endometrial and ovarian carcinomas and primary endometrial cancer with ovarian metastasis / 肿瘤研究与临床

Objective To compare the synchronous primary endometrial and ovarian carcinomas with primary endometrial cancer with ovarian metastasis through analysis the general condition, clinical features, pathologic result,treatment and the prognosis of the two diseases. Methods 24 patients with synchronous primary endometrial and ovarian carcinomas and 27 patients with primary endometrial cancer with ovarian metastasis in Shanxi Cancer Hospital from January 2000 to January 2015 were collected. Results There were statistical significance among age, menopause or not, clinical symptoms, ascites, vascular tumor emboli, tumor differentiation, lymph node metastasis and the prognosis between the two groups (all P< 0.05). The patients with synchronous primary endometrial and ovarian carcinomas were younger, had pelvic mass and stomachache, less ascites, no vascular tumor emboli, well tumor differentiation, no lymph node metastasis. They had better prognosis compared with patients with primary endometrial cancer with ovarian metastasis. Conclusions Patients with synchronous primary endometrial and ovarian carcinomas are younger than patients with primary endometrial cancer with ovarian metastasis,and more early stage, the excessive treatment should be prevented. They have better prognosis compared with patients with primary endometrial cancer with ovarian metastasis.

Identificación de tumor primario en pacientes con metástasis como forma de presentación de cáncer / Identification of the primary tumor in patients with metastases presenting as cancer

INTRODUCCIÓN: hoy día el cáncer compite con la cardiopatía isquémica como primera causa de muerte en Cuba, muy por encima incluso de la enfermedad cerebrovascular, los accidentes y la neumonía. En muchos casos, el cáncer se presenta con metástasis y solo se logra identificar el tumor primario en una parte de ellos, mientras que en el resto, se mantiene "oculto" tras una investigación considerada "óptima". OBJETIVO: determinar la frecuencia con que se identifica en nuestro medio un tumor primario cuando el cáncer se ha presentado con metástasis, la distribución topográfica de los sitios de metástasis y las variantes histológicas en casos de tumor primario "oculto". MÉTODOS: estudio transversal, prospectivo y descriptivo realizado en el Servicio de Medicina Interna del Hospital Clinicoquirúrgico "Hermanos Ameijeiras" en el período comprendido de enero 2010 a enero 2013. El universo de trabajo estuvo constituido por 100 pacientes con metástasis sin primario identificado como diagnóstico de hospitalización, que cumplían los criterios de inclusión. Se utilizaron las variables: localización de tumor primario, sitios de metástasis y variedades histológicas. Se emplearon principalmente métodos de estadística descriptiva, especialmente los aplicables a variables cualitativas (incidencia). RESULTADOS: se logró identificar tumor primario en 50 pacientes. Las localizaciones más frecuentes fueron pulmón (11 %), colon, ovario y próstata (5 % en cada caso). En 50 % de los casos no se identificó tumor primario. El sitio más común de metástasis fue el hígado (56,0 %), seguido por los ganglios (41,0 %) y la pleura pulmón (19,0). En el caso de los pacientes en los que no se logró identificar el tumor primario, la variedad más frecuente fue adenocarcinoma bien diferenciado (42 %) seguida del carcinoma poco diferenciado (34 %) y el carcinoma neuroendocrino (20 %). CONCLUSIONES: en nuestro medio, se logra identificar tumor primario en la mitad de los pacientes que se presentan con metástasis . Ello es independiente del número de metástasis al momento de la presentación. El sitio de afectación metastásica más frecuente es el hígado. La variante histológica predominante entre pacientes con tumor primario "oculto" fue adenocarcinoma.

INTRODUCTION: today cancer competes with ischemic heart disease as the leading cause of death in Cuba, even far above cerebrovascular disease, accidents, and pneumonia. In many cases, cancer has metastasized and only the primary tumor is only identified in a part of them, while in the rest, the tumor remains "hidden" behind a research considered as "optimal". OBJECTIVE: to determine, in our context, how often a primary tumor is identified when the cancer has metastasized, the topographical distribution of metastasis sites and histological variants in cases of "hidden" primary. METHODS: A cross-sectional, prospective and descriptive study was conducted in the Department of Internal Medicine, at Hermanos Ameijeiras Clinical Hospital from January 2010 to January 2013. The working universe consisted of 100 patients with metastasis with no primary tumor identified as diagnosis of hospitalization, who met the inclusion criteria. Location of primary tumor, metastatic sites and histological types were variables used. Descriptive statistics were mainly used, especially those applicable to qualitative variables (incidence). RESULTS: primary tumor was identified in 50 patients. The most common sites were lung (11 %), colon, ovarian and prostate (5 % each). no primary tumor was identified in 50 % of cases. The most common site of metastasis was liver (56.0 %), followed by lymph (41.0 %) lung and pleura (19.0). the most common strain was well-differentiated adenocarcinoma (42 %) in those patients whose primary tumor failed to be identified; followed by the poorly differentiated carcinoma (34 %) and neuroendocrine carcinoma (20 %). CONCLUSIONS: In our context, identifying the primary tumor is achieved in half of the patients with metastases. This is independent of the number of metastases at presentation. Liver is the most common site of metastasis. The predominant histological variant among patients with "hidden" primary was adenocarcinoma.

A Case of Multiple Primary Cancer with Follicular Lymphoma

The incidence of multiple primary cancer (MPC) is low but has been reported occasionally. Although follicular lymphoma is rare in Korea, the incidence is reported to be gradually increasing. We report a case of synchronous and metachronous MPC consisting of esophagus (squamous cell carcinoma), stomach (adenocarcinoma), and ampulla of Vater (extranodal follicular lymphoma grade 1) in a patient diagnosed as follicular lymphoma (grade 3a) six years ago. In a complicated case like ours, concurrent therapeutic control of synchronous MPC and metachronous hematological malignancy is challenging; meticulous examination and prioritized target therapy are essential for patients' survival.

Incidence of Post-transplant Malignancy after Renal Transplantation: Single Center Analysis / 대한이식학회지

BACKGROUND: Immunosuppression after kidney transplantation is associated with increased risk of malignancy, which has become the second most common cause of death among kidney transplant recipients. In this review, we report the incidence of malignancies after kidney transplantation in a single center and evaluate the incidence, characteristics, relationship to immunosuppressive drugs and discuss what clinicians must consider during a follow-up of patients after kidney transplantation. METHODS: Between May 1978 and September 2013, a total of 748 kidney transplant patients who were able to undergo a follow-up process through electronic medical records were enrolled in this retrospective cohort study to determine the potential incidence and types of malignancy that may occur after kidney transplantation and the associated impact on patients and graft survival. RESULTS: Among 748 patients, 63 cases of malignancy appeared in 54 patients (7.2%). Gastrointestinal cancer (12 cases, 19%) and post-transplant lymphoproliferative disorder (12 cases, 19%) were the two most common types of malignancy. The second most common type of malignancy was urinary tract malignancy in 10 patients. Two different types of malignancy were diagnosed in nine patients during our follow-up. The overall graft survival in malignancy patients was better, which may mean that malignancy did not affect the overall graft loss. CONCLUSIONS: Clinicians should be aware of the incidence of malignancy in transplant patients and perform routine examinations for early detection of malignancy.

Clinical Characteristics of Colorectal Cancer Patients With a Second Primary Cancer

PURPOSE: The incidence of colorectal cancer is increasing due to a westernized dietary lifestyle, and improvements in treatment and diagnostic tools have resulted in more patients being confirmed of having multiple primary cancers. However, studies regarding multiple primary cancers are insufficient. In this study, the clinical aspects of patients with primary multiple cancers, including colorectal cancers, were investigated, and the results were compared to those of patients with primary colorectal cancer only. METHODS: Seven hundred eighteen patients who received surgery for colorectal cancer between March 2003 and September 2012 in CHA Medical Center were enrolled. A retrograde cohort was done for comparison of the two groups: those with and those without multiple primary cancer. The analysis was done according to sex, age, tumor location, tumor size, metastatic regional lymph-node number, vascular/lymphatic microinvasion, staging, tumor markers, microsatellite instability, and C/T subgroup of polymorphism in methylenetetrahydrofolate reductase. RESULTS: Of the 718 subjects, 33 (4.6%) had multiple primary cancers: 12 (36.4%) synchronous and 21 (63.6%) metachronous. The malignancy most frequently accompanying colorectal cancer was gastric cancer, followed by thyroid, prostate, and esophageal malignancies in that order. In the comparison between groups, mean age, tumor location, and microsatellite instability showed statistically significant differences; others parameters did not. CONCLUSION: The incidence of multiple primary cancers, including colorectal cancer, is increasing. Therefore, defining the characteristics of patients with multiple primary cancers is crucial, and those characteristics need to be acknowledged in the follow-up of colorectal cancer patients.

Valor del examen post mortem en pacientes con cáncer de tumor primario oculto / Value of the post-mortem examination in patients con hidden primary tumor cancer

Introducción: El cáncer de primario oculto se define como enfermedad neoplásica maligna diseminada, demostrada mediante el estudio anatomopatológico de una de sus metástasis, sin que se consiga identificar el origen del tumor primario, a pesar de un estudio considerado óptimo. Supone el 4-10 por ciento de todos los cánceres que se diagnostican y en 15-25 por ciento de los casos no se detecta ni en las autopsias. Objetivo: Evaluar la utilidad de la autopsia para identificar el tumor primario en pacientes con neoplasias de primario oculto. Métodos: Se realizó un estudio descriptivo, retrospectivo, transversal donde se revisaron todos los protocolos de necropsias del Hospital Hermanos Ameijeiras desde 1994 a 2004. Se seleccionaron aquellos en los que la causa básica de muerte clínica declarada en la certificación de defunción fue metástasis de primario oculto o metástasis de un órgano específico, 95 casos. Se identificaron las variables: localización del tumor primario, variedad histológica, sitios de metástasis, edad, sexo, manifestación clínica preponderante. Resultados: En 94,7 por ciento de los casos fue posible identificar el sitio del tumor primario; las localizaciones más comunes fueron: pulmón (38,95 por ciento), páncreas (14,74 por ciento) y colon (8,42 por ciento) y la variedad histológica encontrada en mayor proporción: adenocarcinoma pobremente diferenciado o carcinoma indiferenciado, seguido del adenocarcinoma bien o moderadamente diferenciado. Los órganos de asiento de metástasis más frecuentes fueron ganglio linfático, hígado y glándula suprarrenal. La forma de presentación clínica más frecuente del cáncer de pulmón fue el dolor óseo, en el cáncer de páncreas y ovario, la ascitis, y en el cáncer de colon, la hepatomegalia tumoral...

Introduction: The hidden primary cancer is defined as a spreading malignant neoplasia disease, demonstrated by the anatomic-pathological study of one of its metastasis without to identify the origin of primary tumor, despite a study considered like "optimal". It is believed that the 4-10 percent of all cancers diagnosed and in the 15-25 percent of the cases is neither detected nor the necropsies. Objective: To assess the usefulness of the necropsies to identify the primary tumor in patients presenting with hidden primary neoplasia. Methods: A cross-sectional, retrospective and descriptive study was conducted to review the necropsy protocols of the "Hermanos Ameijeiras" Clinical Surgical Hospital from 1994 to 2004. Were selected those patients in whom the basic cause of clinical death according to death certificate was the metastasis of a hidden primary tumor of a specific organ, 95 cases. The following variables were identified: location of primary tumor, histological variety, sites of metastasis, age, sex, predominant clinical manifestation. Results: In 94.7 percent of cases it was possible to identify the location of primary tumor. The commonest locations were: lung (38.95 percent), pancreas (14.74 percent) and colon (8.42 percent) and the histological variety founded in a great proportion: poor differentiated adenocarcinoma or undifferentiated carcinoma, followed by the well or slightly moderate adeconocarcinoma. The more frequent sites of metastasis were the lymphatic ganglia, liver and suprarenal gland. The more frequent clinical presentation way of lung cancer was the bone pain, in the cancer of pancreas and ovarium, the ascites, and in the cancer of colon, the humoral hepatomegaly...